The article provides a thorough analysis of the pharmacomodulation effects of different substituents on the 2-aminothiophene scaffold. However, it would be beneficial to elaborate on the potential mechanisms of action of these compounds, particularly how the structural modifications influence their interaction with Leishmania targets. Could the authors provide more insights into the molecular targets or pathways affected by these derivatives, and how this relates to their observed antileishmanial activity?
